Novelgen
Find Us
← Back to list
J&J bets $2.2B on Ollin’s vision loss drug

J&J bets $2.2B on Ollin’s vision loss drug

BioPharma DiveDelilah AlvaradoNovember 16, 2026
The deal hands J J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
Read original article
← Back to list